• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: GBSI addresses irreproducibility of research findings

Report: GBSI addresses irreproducibility of research findings

December 16, 2013
CenterWatch Staff

The Global Biological Standards Institute (GBSI) has presented findings from the first comprehensive report on the state of life science research quality. GBSI commissioned the report to assess the quality of R&D methodologies, identify areas of concern and establish recommendations for meaningful change.

The report, The Case for Standards in Life Science Research: Seizing Opportunities at a Time of Critical Need, addresses the rising concerns associated with irreproducibility of research findings and lays the foundation for a call to action.

"Reproducibility is the foundation of life science research and yet far too often the inability to reproduce experimental data has resulted in the invalidation of research breakthroughs, retraction of published papers and abrupt discontinuation of studies," said Leonard Freedman, Ph.D., president of GBSI. "The global community can no longer afford the economic and intellectual drain, reduced trust in the research enterprise and lost opportunities to expedite discovery of cures and enhance global health."

GBSI commissioned a third-party organization to interview almost 60 stakeholders across the life science community in 2013. The case integrates the findings of these interviews, an extensive review of the literature and other sources, including government agencies and the pharmaceutical industry. One of the key findings is that irreproducibility is a pervasive, systemic problem across research settings and profoundly affects the entire community, from bench scientists to patients.

"Addressing this critical issue must be a top priority for the research community," said C. Glenn Begley, MB, BS, Ph.D., chief science officer and senior vice president, TetraLogic Pharmaceuticals. "This is not an easy task, but we need to remember that improving the reliability of research means greater advances in prevention and cures. Improving systems, including development of standards, will help patients and ultimately save lives."

The case identified a variety of factors that contribute to life science research irreproducibility, but overall, most can be traced to the absence of a unifying standards framework. The concept of standards is not new and has been the foundation of progress in science and technology from Wi-Fi to building bridges. Unlike other fields of endeavor, however, life science research has very few broadly implemented standards.

"All stakeholders interviewed for the case agreed that there is a need for more standards in life science research, and this need has become more urgent as biology enters a new realm of complexity and multidisciplinary approaches to 'omics'," said Freedman. "The environment also is extremely competitive, with a strong drive to translate discoveries into clinical applications, and to do so in a cost-effective way."

GBSI is coordinating a global effort to increase the level of credible, replicable and translatable results in life science research by driving the expanded development and adoption of standards through policy initiatives, thought leadership and education. These efforts will engage and mobilize all stakeholders across the life sciences. 

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing